Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Metabolic Brain Disease
Published in: Metabolic Brain Disease 3/2013

01-09-2013 | Review Article

Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?

Authors: Hutan Ashrafian, Leanne Harling, Ara Darzi, Thanos Athanasiou

Published in: Metabolic Brain Disease | Issue 3/2013

Login to get access

Abstract

Neurodegenerative diseases are amongst the leading causes of worldwide disability, morbidity and decreased quality of life. They are increasingly associated with the concomitant worldwide epidemic of obesity. Although the prevalence of both AD and PD continue to rise, the available treatment strategies to combat these conditions remain ineffective against an increase in global neurodegenerative risk factors. There is now epidemiological and mechanistic evidence associating obesity and its related disorders of impaired glucose homeostasis, type 2 diabetes mellitus and metabolic syndrome with both AD and PD. Here we describe the clinical and molecular relationship between obesity and neurodegenerative disease. Secondly we outline the protective role of weight loss, metabolic and caloric modifying interventions in the context of AD and PD. We conclude that the application of caloric restriction through dietary changes, bariatric (metabolic) surgery and gut hormone therapy may offer novel therapeutic strategies against neurodegenerative disorders. Investigating the protective mechanisms of weight loss, metabolic and caloric modifying interventions can increase our understanding of these major public health diseases and their management.
Literature
Aasheim ET, Elshorbagy AK, My Diep L, Sovik TT, Mala T, Valdivia-Garcia M, Olbers T, Bohmer T, Birkeland KI, Refsum H (2011) Effect of bariatric surgery on sulphur amino acids and glutamate. Br J Nutr 106(3):432–440PubMedCrossRef
Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, Tanner CM, Curb JD, Blanchette PL, Popper JS, Petrovitch H (2002) Midlife adiposity and the future risk of Parkinson’s disease. Neurology 59(7):1051–1057PubMedCrossRef
Accardi G, Caruso C, Colonna-Romano G, Camarda C, Monastero R, Candore G (2012) Can Alzheimer disease be a form of type 3 diabetes? Rejuvenation Res 15(2):217–221PubMedCrossRef
Adlard PA, Perreau VM, Pop V, Cotman CW (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J Neurosci 25(17):4217–4221PubMedCrossRef
Ashrafian H (2011) Bariatric surgery: can we afford to do it or deny doing it? Frontline Gastroenterol 2:82–89PubMedCrossRef
Ashrafian H, le Roux CW (2009) Metabolic surgery and gut hormones—a review of bariatric entero-humoral modulation. Physiol Behav 97(5):620–631PubMedCrossRef
Ashrafian H, le Roux CW, Darzi A, Athanasiou T (2008) Effects of bariatric surgery on cardiovascular function. Circulation 118(20):2091–2102PubMedCrossRef
Ashrafian H, Athanasiou T, Li JV, Bueter M, Ahmed K, Nagpal K, Holmes E, Darzi A, Bloom SR (2010a) Diabetes resolution and hyperinsulinaemia after metabolic Roux-en-Y gastric bypass. Obes Rev 12(5):e257–272
Ashrafian H, Bueter M, Ahmed K, Suliman A, Bloom SR, Darzi A, Athanasiou T (2010b) Metabolic surgery: an evolution through bariatric animal models. Obes Rev 11(12):907–920PubMedCrossRef
Ashrafian H, Darzi A, Athanasiou T (2010c) Autobionics: a new paradigm in regenerative medicine and surgery. Regen Med 5(2):279–288PubMedCrossRef
Ashrafian H, Ahmed K, Rowland SP, Patel VM, Gooderham NJ, Holmes E, Darzi A, Athanasiou T (2011a) Metabolic surgery and cancer: protective effects of bariatric procedures. Cancer 117(9):1788–1799PubMedCrossRef
Ashrafian H, le Roux CW, Rowland SP, Ali M, Cummin AR, Darzi A, Athanasiou T (2011b) Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. Thorax 67(5):442–449
Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L (2008) Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am Geriatr Soc 56(1):111–116PubMedCrossRef
Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H (2012) Alzheimer’s disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. CurrAlzheimer research 9(5):563–573
Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2001) Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case–control study. Mov Disord 16(5):830–837PubMedCrossRef
Bhattacharyya R, Kovacs DM (2010) ACAT inhibition and amyloid beta reduction. Biochim Biophys Acta 1801(8):960–965PubMedCrossRef
Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH (2012) Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer research 9(5):574–588
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 3(3):186–191PubMedCrossRef
Brozinick JT, Hawkins E, Hoang Bui H, Kuo MS, Tan B, Kievit P, Grove K (2012) Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes. doi:10.​1038/​ijo.​2012.​191
Bruce-Keller AJ, Umberger G, McFall R, Mattson MP (1999) Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann Neurol 45(1):8–15PubMedCrossRef
Buxbaum JD, Geoghagen NS, Friedhoff LT (2001) Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J Alzheimers Dis 3(2):221–229PubMed
Chen D, Steele AD, Hutter G, Bruno J, Govindarajan A, Easlon E, Lin SJ, Aguzzi A, Lindquist S, Guarente L (2008) The role of calorie restriction and SIRT1 in prion-mediated neurodegeneration. Exp Gerontol 43(12):1086–1093PubMedCrossRef
Chen JQ, Brown TR, Russo J (2009) Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased exposure to endocrine disruptors. Biochim Biophys Acta 1793(7):1128–1143PubMedCrossRef
Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55(11):1449–1455PubMedCrossRef
Cohn-Hokke PE, Elting MW, Pijnenburg YA, van Swieten JC (2012) Genetics of dementia: update and guidelines for the clinician. Am J Med Genet Part B, Neuropsychiatr Genet : Off Publ Int Soc Psychiatr Genet 159B(6):628–643CrossRef
Contestabile A (2009) Benefits of caloric restriction on brain aging and related pathological States: understanding mechanisms to devise novel therapies. Curr Med Chem 16(3):350–361PubMedCrossRef
Counts SE, Perez SE, Ginsberg SD, Mufson EJ (2010) Neuroprotective role for galanin in Alzheimer’s disease. EXS 102:143–162PubMed
Craft S, Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3(3):169–178PubMedCrossRef
D’Amico M, Di Filippo C, Marfella R, Abbatecola AM, Ferraraccio F, Rossi F, Paolisso G (2010) Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice. Exp Gerontol 45(3):202–207PubMedCrossRef
Di Paolo G, Kim TW (2011) Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat Rev Neurosci 12(5):284–296PubMedCrossRef
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68(5):384–386PubMedCrossRef
Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J Neurosci Res 57(2):195–206PubMedCrossRef
Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 80(1):101–110PubMedCrossRef
Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF (2011) Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A 108(7):3017–3022PubMedCrossRef
Farias MM, Cuevas AM, Rodriguez F (2011) Set-point theory and obesity. Metab Syndr Relat Disord 9(2):85–89PubMedCrossRef
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100(7):4162–4167PubMedCrossRef
Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302(6):638–648PubMedCrossRef
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74(12):956–964PubMedCrossRef
Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, Estes JD, Dodiya HB, Keshavarzian A (2011) Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 6(12):e28032PubMedCrossRef
Gahete MD, Rubio A, Cordoba-Chacon J, Gracia-Navarro F, Kineman RD, Avila J, Luque RM, Castano JP (2010) Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer’s disease patients. J Alzheimers Dis 22(3):819–828PubMed
Gahete MD, Cordoba-Chacon J, Kineman RD, Luque RM, Castano JP (2011) Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer’s disease. Peptides 32(11):2225–2228PubMedCrossRef
Gamba P, Testa G, Sottero B, Gargiulo S, Poli G, Leonarduzzi G (2012) The link between altered cholesterol metabolism and Alzheimer’s disease. Ann N Y Acad Sci 1259:54–64PubMedCrossRef
Gao H, Wang X, Zhang Z, Yang Y, Yang J, Li X, Ning G (2007) GLP-1 amplifies insulin signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. Endocrine 32(1):90–95PubMedCrossRef
Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63(2):168–174PubMedCrossRef
Gault VA, Holscher C (2008) GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol 587(1–3):112–117PubMedCrossRef
Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahren B, Betsholtz C (1998) Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250(2):271–277PubMedCrossRef
Gilbey SG, Stephenson J, O’Halloran DJ, Burrin JM, Bloom SR (1989) High-dose porcine galanin infusion and effect on intravenous glucose tolerance in humans. Diabetes 38(9):1114–1116PubMedCrossRef
Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I (2003) An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 163(13):1524–1528PubMedCrossRef
Hao Z, Wu B, Wang D, Liu M (2011) Association between metabolic syndrome and cognitive decline: a systematic review of prospective population-based studies. Acta Neuropsychiatr 23:69–74CrossRef
Harkavyi A, Whitton PS (2010) Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 159(3):495–501PubMedCrossRef
Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation 5:19PubMedCrossRef
Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G (1996) Diet and Parkinson’s disease. II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case–control study. Neurology 47(3):644–650PubMedCrossRef
Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL (2001) Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 285(6):739–747PubMedCrossRef
Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57(6):846–851PubMedCrossRef
Holscher C (2012) Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection. CNS Drugs 26(10):871–882PubMedCrossRef
Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27(3):547–558PubMedCrossRef
Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42(4):427–434PubMedCrossRef
Hoppener JW, Ahren B, Lips CJ (2000) Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343(6):411–419PubMedCrossRef
Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 166(1):127–135PubMedCrossRef
Ittner LM, Gotz J (2011) Amyloid-beta and tau–a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12(2):65–72PubMedCrossRef
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474–481PubMedCrossRef
Jazet IM, de Groot GH, Tuijnebreyer WE, Fogteloo AJ, Vandenbroucke JP, Meinders AE (2007) Cardiovascular risk factors after bariatric surgery: do patients gain more than expected from their substantial weight loss? Eur J Intern Med 18(1):39–43PubMedCrossRef
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356(9242):1627–1631PubMedCrossRef
Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL (1999) Adult nutrient intake as a risk factor for Parkinson’s disease. Int J Epidemiol 28(6):1102–1109PubMedCrossRef
Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (2012) The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60(10):875–881PubMedCrossRef
Jyvakorpi SK, Puranen T, Pitkala KH, Suominen MH (2012) Nutritional treatment of aged individuals with Alzheimer disease living at home with their spouses: study protocol for a randomized controlled trial. Trials 13:66PubMedCrossRef
Kim Chung le T, Hosaka T, Yoshida M, Harada N, Sakaue H, Sakai T, Nakaya Y (2009) Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 390(3):613–618PubMedCrossRef
Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer’s disease and amyotrophic lateral sclerosis. EMBO J 26(13):3169–3179PubMedCrossRef
Kim S, Moon M, Park S (2009) Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson’s disease. J Endocrinol 202(3):431–439PubMedCrossRef
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322(7300):1447–1451PubMedCrossRef
Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20(18):6920–6926PubMed
Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci 22(5):1752–1762PubMed
Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Przuntek H, Kretschmer A, Buttner T, Woitalla D, Muller T (1998) Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 40(4):225–227PubMedCrossRef
Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120(5):701–713PubMedCrossRef
Lee J, Duan W, Long JM, Ingram DK, Mattson MP (2000) Dietary restriction increases the number of newly generated neural cells, and induces BDNF expression, in the dentate gyrus of rats. J Mol Neurosci 15(2):99–108PubMedCrossRef
Lee J, Seroogy KB, Mattson MP (2002) Dietary restriction enhances neurotrophin expression and neurogenesis in the hippocampus of adult mice. J Neurochem 80(3):539–547PubMedCrossRef
Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, Palumbo PJ (1997) Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 145(4):301–308PubMedCrossRef
Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH (2010) GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19(4):1205–1219PubMed
Li JV, Ashrafian H, Bueter M, Kinross J, Sands C, le Roux CW, Bloom SR, Darzi A, Athanasiou T, Marchesi JR, Nicholson JK, Holmes E (2011a) Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut 60(9):1214–1223
Li XH, Lv BL, Xie JZ, Liu J, Zhou XW, Wang JZ (2011b) AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging 33(7):1400–1410
Liu L, Martin R, Chan C (2013) Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. Neurobiol Aging 34(2):540–550PubMedCrossRef
Livhits M, Mercado C, Yermilov I, Parikh JA, Dutson E, Mehran A, Ko CY, Gibbons MM (2010) Exercise following bariatric surgery: systematic review. Obes Surg 20(5):657–665PubMedCrossRef
Logroscino G, Marder K, Cote L, Tang MX, Shea S, Mayeux R (1996) Dietary lipids and antioxidants in Parkinson’s disease: a population-based, case–control study. Ann Neurol 39(1):89–94PubMedCrossRef
Luchsinger JA, Tang MX, Shea S, Mayeux R (2002) Caloric intake and the risk of Alzheimer disease. Arch Neurol 59(8):1258–1263PubMedCrossRef
Mattson MP (2003) Will caloric restriction and folate protect against AD and PD? Neurology 60(4):690–695PubMedCrossRef
Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S (1999) Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer’s and Parkinson’s diseases. Ann N Y Acad Sci 893:154–175PubMedCrossRef
Mattson MP, Duan W, Guo Z (2003) Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J Neurochem 84(3):417–431PubMedCrossRef
McCue MD (2010) Starvation physiology: reviewing the different strategies animals use to survive a common challenge. Comp Biochem Physiol Part A, Mol & integr Physiol 156(1):1–18CrossRef
McIntyre RS, Powell AM, Kaidanovich-Beilin O, Soczynska JK, Alsuwaidan M, Woldeyohannes HO, Kim AS, Gallaugher LA (2012) The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res 237C:164–171
Milionis HJ, Florentin M, Giannopoulos S (2008) Metabolic syndrome and Alzheimer’s disease: a link to a vascular hypothesis? CNS spectrums 13(7):606–613PubMed
Mitsutake S, Igarashi Y (2013) Sphingolipids in lipid microdomains and obesity. Vitam Horm 91:271–284PubMedCrossRef
Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR (1996) Case–control study of idiopathic Parkinson’s disease and dietary vitamin E intake. Neurology 46(5):1270–1274PubMedCrossRef
Mosselman S, Hoppener JW, Zandberg J, van Mansfeld AD, Geurts van Kessel AH, Lips CJ, Jansz HS (1988) Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett 239(2):227–232PubMedCrossRef
Mutch DM, Fuhrmann JC, Rein D, Wiemer JC, Bouillot JL, Poitou C, Clement K (2009) Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One 4(11):e7905PubMedCrossRef
Muzumdar RH, Huffman DM, Atzmon G, Buettner C, Cobb LJ, Fishman S, Budagov T, Cui L, Einstein FH, Poduval A, Hwang D, Barzilai N, Cohen P (2009) Humanin: a novel central regulator of peripheral insulin action. PLoS One 4(7):e6334PubMedCrossRef
Opie EL (1901) The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islands of Langerhans. J Exp Med 5:527–540PubMedCrossRef
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9):1937–1942PubMedCrossRef
Patil S, Melrose J, Chan C (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci 26(8):2131–2141PubMedCrossRef
Perl DP, Olanow CW, Calne D (1998) Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 44(3 Suppl 1):S19–S31PubMed
Perry TA, Greig NH (2004) A new Alzheimer’s disease interventive strategy: GLP-1. Curr Drug Targets 5(6):565–571PubMedCrossRef
Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881–888PubMedCrossRef
Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 72(5):603–612PubMedCrossRef
Plunet WT, Streijger F, Lam CK, Lee JH, Liu J, Tetzlaff W (2008) Dietary restriction started after spinal cord injury improves functional recovery. Exp Neurol 213(1):28–35PubMedCrossRef
Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton PS (2012) Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions. Neuropeptides 46(5):183–193PubMedCrossRef
Rebeck GW, Kindy M, LaDu MJ (2002) Apolipoprotein E and Alzheimer’s disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 4(3):145–154PubMed
Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451–458PubMedCrossRef
Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J 6(4):246–254PubMed
Rogers BS, Lippa CF (2012) A clinical approach to early-onset inheritable dementia. AJADD 27(3):154–161
Russell MB (2010) Genetics of dementia. Acta Neurol Scandinavica Suppl 190:58–61CrossRef
Sandyk R (1993) The relationship between diabetes mellitus and Parkinson’s disease. Int J Neurosci 69(1–4):125–130PubMedCrossRef
Sato N, Takeda S, Uchio-Yamada K, Ueda H, Fujisawa T, Rakugi H, Morishita R (2011) Role of insulin signaling in the interaction between alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr Aging Sci 4(2):118–127
Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA, Yu MC (2001) Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 73(2):232–239PubMed
Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y (2009) Physical activity, diet, and risk of Alzheimer disease. JAMA 302(6):627–637PubMedCrossRef
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346(7):476–483PubMedCrossRef
Session DR, Pearlstone MM, Jewelewicz R, Kelly AC (1994) Estrogens and Parkinson’s disease. Med Hypotheses 42(4):280–282PubMedCrossRef
Sharma S, Kaur G (2005) Neuroprotective potential of dietary restriction against kainate-induced excitotoxicity in adult male Wistar rats. Brain Res Bull 67(6):482–491PubMedCrossRef
Sheard JM, Ash S, Silburn PA, Kerr GK (2013) Nutritional status in Parkinson’s disease patients undergoing deep brain stimulation surgery: a pilot study. J Nutr, health Aging 17(2):148–151CrossRef
Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351(26):2683–2693PubMedCrossRef
Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8):741–752PubMedCrossRef
Sledzinski T, Goyke E, Smolenski RT, Sledzinski Z, Swierczynski J (2011) Decreased serum betaine concentrations in patients after bariatric surgery. Obes Surg 21(10):1634–1639
Sriram K, Benkovic SA, Miller DB, O’Callaghan JP (2002) Obesity exacerbates chemically induced neurodegeneration. Neuroscience 115(4):1335–1346PubMedCrossRef
Steel JH, Gon G, O’Halloran DJ, Jones PM, Yanaihara N, Ishikawa H, Bloom SR, Polak JM (1989) Galanin and vasoactive intestinal polypeptide are colocalised with classical pituitary hormones and show plasticity of expression. Histochemistry 93(2):183–189PubMedCrossRef
Stewart R, Masaki K, Xue QL, Peila R, Petrovitch H, White LR, Launer LJ (2005) A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 62(1):55–60PubMedCrossRef
Stolk RP, Breteler MM, Ott A, Pols HA, Lamberts SW, Grobbee DE, Hofman A (1997) Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care 20(5):792–795PubMedCrossRef
Suzuki K, Katzman R, Korey SR (1965) Chemical studies on Alzheimer’s disease. J Neuropathol Exp Neurol 24:211–224PubMedCrossRef
Swerdlow RH, Burns JM, Khan SM (2010) The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2):S265–S279PubMed
Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA, Morris MC (2011) Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 93(3):601–607PubMedCrossRef
van Echten-Deckert G, Walter J (2012) Sphingolipids: critical players in Alzheimer’s disease. Progr Lipid Res 51(4):378–393CrossRef
Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS (2001) Brain dopamine and obesity. Lancet 357(9253):354–357PubMedCrossRef
Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF Abeta42 levels in normal older adults. Neurology 60(12):1899–1903PubMedCrossRef
Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Frolich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer’s disease. Neurobiol Aging 27(1):38–41PubMedCrossRef
Whitmer RA, Gustafson DR, Barrett-Connor E, Haan MN, Gunderson EP, Yaffe K (2008) Central obesity and increased risk of dementia more than three decades later. Neurology 71(14):1057–1064PubMedCrossRef
Wolf SA, Kronenberg G, Lehmann K, Blankenship A, Overall R, Staufenbiel M, Kempermann G (2006) Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer’s disease. Biol Psychiatry 60(12):1314–1323PubMedCrossRef
Woodard GA, Peraza J, Bravo S, Toplosky L, Hernandez-Boussard T, Morton JM (2010) One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg 20(5):578–582PubMedCrossRef
World Alzheimer Report 2010: The Global Economic Impact of Dementia (2010). Alzheimer’s Disease International, London
Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2011) Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 76(18):1568–1574PubMedCrossRef
Yu ZF, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration reduce focal ischemic brain damage and improve behavioral outcome: evidence for a preconditioning mechanism. J Neurosci Res 57(6):830–839PubMedCrossRef
Zhu H, Guo Q, Mattson MP (1999) Dietary restriction protects hippocampal neurons against the death-promoting action of a presenilin-1 mutation. Brain Res 842(1):224–229PubMedCrossRef
Metadata
Title
Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?
Authors
Hutan Ashrafian
Leanne Harling
Ara Darzi
Thanos Athanasiou
Publication date
01-09-2013
Publisher
Springer US
Published in
Metabolic Brain Disease / Issue 3/2013
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-013-9412-4

Other articles of this Issue 3/2013

Metabolic Brain Disease 3/2013 Go to the issue

Original Paper

IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke

Original Paper

Methylglyoxal-induced cytotoxicity in neonatal rat brain: a role for oxidative stress and MAP kinases

Editorial

Measurement of subclinical carotid atherosclerosis may help in predicting risk for stroke in patients with diabetes

Short Communication

Congenital MTHFR deficiency causing early-onset cerebral stroke in a case homozygous for MTHFR thermolabile variant

Original Paper

Influence of BDNF polymorphisms on Wilson’s disease susceptibility and clinical course

Original Paper

Cognitive assessment of patients with minimal hepatic encephalopathy in Brazil